R&D Inquiry
Intellectual Property (IP):
Aptagen owns the proprietary process of aptamer development; however, the Client will own 100% of the rights to the aptamers Aptagen develops for the Client. Client contracts Aptagen to perform the R&D, the Client owns the IP.
PRICE MATCH GUARANTEE: Contact Us. We will make every effort to match any competitor’s quote (for equivalent services). Just provide documentation. Thank you.
Depending on Client needs, the project may be tailored to meet certain milestone objectives such as:
- High Affinity (Kd) AND High Specificity; eliminate (false-positive) cross-reactivity.
- Wide dynamic range between positive and negative samples (LOD)
- Activation (EC50) or inhibition (IC50) against a target enzyme
- Identification of unknown and unique biomarkers in serum, blood, or tissue samples
- Cell or tissue-targeting for drug delivery
- Convert an already existing aptamer into an apta-beacon™ to detect analytes free in solution (see Apta-Beacons™)
Description | Target Type |
|---|---|
Iterative rounds of screening an initial random library against a target for positive selection, and counter-selection against a counter-target for specificity. Client Materials: Please note that the Client will need to provide the target(s) for Aptagen. It is highly recommended that countertarget(s) is also provided for enrichment of highly specific apta-sensors. A Material Acquisition Form must be completed for background information on the target, any associated hazards, and handling requirements. | Small Targets: Small Molecules or Peptides Large Targets: Proteins, Biomarkers, Cells, Tissues Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.  |
Small Molecules or Peptides
Proteins or high MW Biomarkers
Cell Based
Ex Vivo (tissue)
Whole Animal
Description | Deliverable |
|---|---|
The enriched polyclonal pool is sequenced and thousands of apta-sensor sequences are provided. Client will have access to all the data generated from the polyclonal apta-sensor pool in Phase I (hundreds to thousands of sequences). | Deliverable: The most promising monoclonal apta-sensor candidates are identified using proprietary bioinformatics. A full Progress/Analysis Report on a handful of the most likely candidates based on sequence homology, frequency, and motif analysis.  |
Description | Deliverable |
|---|---|
Monoclonal apta-sensor oligo candidate(s) are synthesized, purified, and QC. Projects are typically based on unmodified apta-sensors.
Note: This Phase is at the Client’s discretion whether Aptagen performs the work or is performed by another provider. | Deliverable: 1 nmole of purified apta-sensors for Phase IV  |
Description | Assay Type |
|---|---|
Each tested for assessing Kd affinities, signal-to-background, LOD, targeting, or EC50/IC50, etc..
Note: This Phase is at the Client’s discretion whether Aptagen performs the work or is performed by another provider. | ForteBio, Thermophoresis, Dot Blot, Gel-shift assay, or ELONA (ELISA), Microscopy, Flow Cytometry, or Imaging, etc
Deliverable: Full Report on Kd Affinities and Specificities.  |
Description | Deliverable: |
|---|---|
At the Client’s discretion, Aptagen may ‘multimerize’ apta-sensors to further enhance functional properties of apta-sensor candidate(s) while truncating or minimizing the length of the oligo to reduce large-scale manufacturing costs and processing time downstream. Aptagen’s proprietary in silico algorithm searches and explores ‘sequence space.’ Inquire. Project specific. The Optimization Phase may not be necessary for research purposes. This phase entails truncation of apta-sensor oligos to reduce production costs for commercialization or ‘multimerization’ of apta-sensors to further increase affinity/avidity. This Phase may trigger only if Client believes Optimization a) is cost effective to minimize production costs while maximizing activity for large-scale commercial use and/or, b) widens the claims in Client’s IP to strengthen the coverage of all possible apta-sensor sequence variants. | Deliverable: Full Report on Kd Affinities and Specificities. Aptagen validates monoclonal candidates. At least one (1) aptamer candidate must meet Anticipated Milestone Outcome.  |
Academic Collaborations
We are seeking researchers from academia and industry who are interested in pursuing a joint collaborative research project.
The aim is to secure grant funding for each proposed research project. The grant funding process may be in collaboration with researchers, investigators, and specialists from outside the company to garner external expertise in the field of study. The grant funding and peer-review process allows for an unbiased assessment of project feasibility and merit which, we believe, increases the chances of a successful project outcome. Conditions for Collaboration:
- Research Collaborators will be responsible for grant writing and submission.
- Aptagen will provide the necessary aptamer-related text for the manuscript and assist in submission.
- Aptagen is a fee-for-service company and will not begin preliminary research work unless funding is in place.
- Click here for R&D Inquiry and complete the form to calculate the estimated cost for budgeting Aptagen’s subcontract work.
Please provide your contact information and a brief description of your research idea using the Contact Us form.
Increase Your Success with Aptagen Flyer.pdf
